Editas Medicine Announces New Safety and Efficacy Data from
All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post-renizgamglogene autogedtemcel (reni-cel) ...
Read moreAll patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post-renizgamglogene autogedtemcel (reni-cel) ...
Read moreAll patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusion Patients had early normalization ...
Read moreSYDNEY, Australia, June 06, 2024 (GLOBE NEWSWIRE) -- EnGeneIC, a clinical-stage biopharmaceutical company pioneering the development of a First-in-Class targeted ...
Read moreARC Therapy™ shown to be safe and effective in global pivotal trial* 90% of participants improved either strength or function ...
Read moreAUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- In the fast-paced world of sports medicine, few names command as much ...
Read more-- Announced FDA clearance of first-ever IND application for a Prime Editing product, PM359, for the treatment of CGD; initial ...
Read moreThe global market of no- and low-alcohol beverages estimated at over $13 billion in 2023 Vancouver, Canada, May 10, 2024 ...
Read moreOral presentations include updated results from clinical study of otoferlin gene therapy DB-OTO demonstrating restoration in children with profound genetic ...
Read moreDetailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, ...
Read moreWATERTOWN, Mass., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, ...
Read more© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.
© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.